5
Jan
2018
Spark Sets $850K Bar, Microsoft’s Bet on AI for Immune Mapping, & Startup Financings Galore
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jan
2018
Microsoft Makes Nine-Figure Bet on Adaptive’s TCR-Antigen Map; BioNTech Hauls in $270M for 10-Drug Cancer Pipeline
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Scholar Rock, After a Year on Pause, Snags $47M to Take New Tack Against SMA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Jan
2018
Finding a Path in Biotech VC: The Long Run Podcast With Bob More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Dec
2017
How Did BioMarin Make It? The Long Run Podcast With Daniel Levine & Dan Maher
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Dec
2017
Walk & Talk With Me on Powell Street at #JPM18
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Dec
2017
A16Z Rakes in New $450M Fund to Build ‘Engineering Biology’ Plays
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Dec
2017
Accelerator, Backed by Corporate VCs, Spreads Wings – But Not in Boston & SF
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Dec
2017
Biotech’s Test: Root for a Tax Windfall Or Support the Next Generation of Scientists?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Dec
2017
Sage Crushes Depression Trial, Spark’s Hemophilia Tour de Force, & CVS-Aetna Megadeal
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
Obsidian Therapeutics Gets $49.5M to Bring CAR-T Dosing Under Control
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Dec
2017
The Long Run Podcast: Steve Graham on Racism in Corporate America
Steve Graham is today’s guest on The Long Run podcast. Chances are you don’t know his name, but Graham is a major behind-the-scenes player in biotech. Graham is the co-chair of the life sciences practice at the law firm Fenwick & West, and managing partner of the firm’s Seattle office. He has been working with biotech boards, handling corporate law,... Read More
1
Dec
2017
Foundation Medicine Wins FDA/CMS Two-Fer, Azar Calls Out High Drug Prices & Biogen Buys MS Challenger
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2017
The Long Run Podcast: Steve Holtzman on Becoming a Biotech Political Activist
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2017
Codiak, Aspiring to Make Exosome Drugs for Cancer, Nabs $76M to March Into Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2017
How Will the Great Sex Predator Purge Alter Gender Dynamics at Work?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Nov
2017
Former Lilly Exec To Lead HHS, a Flurry of FDA Approvals, & Gates Bets $100M on Alzheimer’s
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Nov
2017
The Oxygen-Providing, High-Autonomy M&A Model: A Sign of Things to Come
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Nov
2017
Sage’s Salvo At Postpartum Depression, Sarepta’s Two Steps Ahead, & Barron Jumps to GSK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Nov
2017
The Long Run Podcast: Elias Zerhouni on the Role of Immigrants In Science
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.